Regencell Bioscience Holdings Limited (RGC) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Regencell Bioscience Holdings Limited (RGC) Earnings Overview
As of June 24, 2026, Regencell Bioscience Holdings Limited (RGC) reported trailing twelve-month net income of -$4M. The company earned $-0.01 per diluted share over the past four quarters.
Looking at the long-term picture, RGC's historical earnings data spans multiple years. The company achieved its highest annual net income of -$390,990 in fiscal 2019.
Regencell Bioscience Holdings Limited is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NUVB (-$146M net income, -325.3% margin), AEYE (-$4M net income, -7.6% margin), SIGA ($20M net income, 24.6% margin), RGC has comparable earnings metrics. Compare RGC vs NUVB →
RGC Earnings vs Peers
Earnings metrics vs comparable public companies
RGC Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$4M | +16.7% | -$4M | $-0.01 | - | - |
| 2024 | -$4M | +26.7% | -$5M | $-0.01 | - | - |
| 2023 | -$6M | +20.9% | -$6M | $-0.01 | - | - |
| 2022 | -$7M | -451.2% | -$8M | $-0.01 | - | - |
| 2021 | -$1M | -65.8% | -$1M | $-0.00 | - | - |
| 2020 | $-812,371 | -107.8% | $-812,371 | $-0.00 | - | - |
| 2019 | $-390,990 | - | $-390,990 | $-0.00 | - | - |
Download Data
Export RGC earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RGC — Frequently Asked Questions
Quick answers to the most common questions about buying RGC stock.
What is RGC earnings per share (EPS)?
RGC trailing twelve-month (TTM) diluted EPS is $-0.01, reflecting N/A year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Regencell Bioscience Holdings Limited's net income?
Regencell Bioscience Holdings Limited (RGC) trailing twelve-month net income is $-4M as of 2025. Earnings declined N/A year-over-year.
Is RGC profitable?
RGC is not currently profitable on a TTM basis, reporting a net loss of $-4M. Net margin is N/A. Investors should monitor for a return to profitability.
What is RGC's earnings growth rate?
RGC compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are RGC's profit margins?
Regencell Bioscience Holdings Limited net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -54.8%.
Is RGC growing earnings?
RGC TTM EPS: $-0.01. Net income: $-4M. YoY earnings change: N/A.
What was RGC's best earnings year?
Regencell Bioscience Holdings Limited's highest annual net income on record is $-390990.00, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were RGC's earnings last quarter?
RGC's most recent reported quarter was Q4 2025. Net income was $-2M with diluted EPS of $-0.00. For a full breakdown of all quarters, see the quarterly earnings table on this page.